Table 1.

Histone deacetylase (HDAC) inhibitors in hepatocellular carcinoma (HCC) treatment (unapproved from the US Food and Drug Administration (FDA)).

HDACis	Specificity	Experimental Design	Clinical Trial of HCC	References
Resminostat (4SC-201)	Classes I and II	Patient with Hepatocelluler carcinoma	Phase II trial	[34]
Quisinostat (JNJ-26481585)	Class I and II HDACs	HCC cell lines	Preclinical	[35]
MPT0E028	HDAC1, 2, 6	Patient with Hepatocelluler carcinoma	Under Phase I trial	clinicaltrials.gov
CUDC-101	Classes I and II HDAC, EGFR, HER2	HCC cell lines	Preclinical	[36]
Entinostat (MS-275)	HDAC1, 2, 3	HCC cell lines	Preclinical	[37]
Valproic acid (VPA)	Class I and II	HCC cell lines Mouse model	Preclinical	[38,39,40]
AR-42	Class I and IIb	HCC cell lines	Preclinical	[41]
Apicidin	HDAC1, 2, 3	HCC cell lines Mouse model	Preclinical	[42]
PCI-34051	HDAC8	HCC cell lines Mouse model	Preclinical	[19]